Fremont, CA — October 25, 2007 – Optovue, Inc., the first company to introduce a Fourier-domain optical coherence tomography (FD-OCT) system to the US market, today announced that on September 28, FDA 510(k) clearance was received for its Cornea/Anterior Module (CAM).

The CAM is an optional attachment for the RTVue, Optovue’s high-speed and high-resolution FD-OCT device for retinal imaging. The CAM add-on enhances the RTVue by enabling five-micron resolution, high-magnification imaging of the cornea, angle and anterior crystalline lens, as well as pachymetry mapping and keratoconus analysis. Together with the retina and glaucoma scanning and analysis functions already provided by the RTVue, the CAM allows the first all-in-one solution for posterior and anterior high-speed, high-resolution OCT imaging.

Optovue founder and CEO Jay Wei commented, “The CAM for the RTVue system is in line with our overall strategy to lead the development and introduction of FD-OCT products into the market. The CAM is a product of our commitment to providing the most comprehensive OCT system on the market. By leveraging our experience in OCT product development and Fourier-domain technology, we will continue to expand our product portfolio to better serve the needs of physicians and patients.”

About Optovue

Optovue, Inc., is a privately-held ophthalmic diagnostic company located in Fremont, California. Optovue was founded in 2003 by ophthalmic industry veterans, including developers of the OCT devices sold by Carl Zeiss Meditec (Humphrey), such as StratusTM and VisanteTM. Optovue has assembled a world-class advisory board comprised of thought leaders in ocular disease diagnosis and treatment, including the original inventors of OCT. Optovue is backed by experienced technology and healthcare venture capital firms and private investors.

Optovue launched the RTVue, the first FDA cleared FD-OCT, at the 2006 Annual Meeting of the American Academy of Ophthalmology. Optovue continues to develop innovative products that will expand the clinical utility of OCT and promote ocular health.
www.optovue.com

For further information, please contact:
Jay Wei
President/CEO

Paul Kealey
VP Sales & Marketing

Back to News